Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

SELLAS Life Sciences Group, Inc. (SLS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.07-0.23 (-4.34%)
At close: 04:00PM EST
5.02 -0.05 (-0.99%)
After hours: 05:33PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.30
Open5.22
Bid5.00 x 2900
Ask5.50 x 1200
Day's Range5.01 - 5.35
52 Week Range5.01 - 15.08
Volume155,923
Avg. Volume153,091
Market Cap80.539M
Beta (5Y Monthly)1.67
PE Ratio (TTM)N/A
EPS (TTM)-1.26
Earnings DateMar 21, 2022 - Mar 25, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.83
  • GlobeNewswire

    SELLAS Life Sciences Promotes John Burns to Senior Vice President, Finance and Chief Accounting Officer

    NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that John T. Burns has been promoted within the Company to Senior Vice President, Finance, and Chief Accounting Officer. “John is an invaluable member of our small, yet nimble SELLAS team. He consistently demonstrates his expertise

  • Simply Wall St.

    Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    SELLAS Life Sciences Announces Final Court Approval of Settlement of Derivative Litigation

    Claims in Derivative Suits Related to Activities of SELLAS’ Predecessor, Galena Biopharma, Inc.NEW YORK, Nov. 23, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that on November 19, 2021 the United States District Court for the District of New Jersey (the "Court") issued the final approval of the

Advertisement
Advertisement